ZA987804B - A combination of a monoamine oxidase inhibitor and a H5-HT1b antagonists or agonist - Google Patents

A combination of a monoamine oxidase inhibitor and a H5-HT1b antagonists or agonist

Info

Publication number
ZA987804B
ZA987804B ZA987804A ZA987804A ZA987804B ZA 987804 B ZA987804 B ZA 987804B ZA 987804 A ZA987804 A ZA 987804A ZA 987804 A ZA987804 A ZA 987804A ZA 987804 B ZA987804 B ZA 987804B
Authority
ZA
South Africa
Prior art keywords
agonist
combination
monoamine oxidase
oxidase inhibitor
ht1b antagonists
Prior art date
Application number
ZA987804A
Other languages
English (en)
Inventor
Stefan Berg
Svante Ross
Seth-Olov Thorberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of ZA987804B publication Critical patent/ZA987804B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA987804A 1997-09-18 1998-08-27 A combination of a monoamine oxidase inhibitor and a H5-HT1b antagonists or agonist ZA987804B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703376A SE9703376D0 (sv) 1997-09-18 1997-09-18 A new combination

Publications (1)

Publication Number Publication Date
ZA987804B true ZA987804B (en) 1999-03-18

Family

ID=20408296

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA987804A ZA987804B (en) 1997-09-18 1998-08-27 A combination of a monoamine oxidase inhibitor and a H5-HT1b antagonists or agonist

Country Status (27)

Country Link
US (1) US6159970A (cg-RX-API-DMAC10.html)
EP (1) EP1014986B1 (cg-RX-API-DMAC10.html)
JP (1) JP2001516719A (cg-RX-API-DMAC10.html)
KR (2) KR20010024087A (cg-RX-API-DMAC10.html)
CN (1) CN1278727A (cg-RX-API-DMAC10.html)
AR (1) AR013503A1 (cg-RX-API-DMAC10.html)
AT (1) ATE270889T1 (cg-RX-API-DMAC10.html)
AU (1) AU752719B2 (cg-RX-API-DMAC10.html)
BR (1) BR9812236A (cg-RX-API-DMAC10.html)
CA (1) CA2302204A1 (cg-RX-API-DMAC10.html)
DE (1) DE69825062T2 (cg-RX-API-DMAC10.html)
DK (1) DK1014986T3 (cg-RX-API-DMAC10.html)
EE (1) EE200000146A (cg-RX-API-DMAC10.html)
ES (1) ES2222603T3 (cg-RX-API-DMAC10.html)
HU (1) HUP0100621A2 (cg-RX-API-DMAC10.html)
ID (1) ID25789A (cg-RX-API-DMAC10.html)
IL (1) IL134775A0 (cg-RX-API-DMAC10.html)
IS (1) IS5401A (cg-RX-API-DMAC10.html)
MX (1) MXPA00002616A (cg-RX-API-DMAC10.html)
NO (1) NO20001400L (cg-RX-API-DMAC10.html)
PL (1) PL339368A1 (cg-RX-API-DMAC10.html)
PT (1) PT1014986E (cg-RX-API-DMAC10.html)
SE (1) SE9703376D0 (cg-RX-API-DMAC10.html)
SK (1) SK2832000A3 (cg-RX-API-DMAC10.html)
TR (1) TR200000725T2 (cg-RX-API-DMAC10.html)
WO (1) WO1999013878A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA987804B (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957948A (en) * 1988-05-05 1990-09-18 Interface, Inc. Biocidal protective coating for heat exchanger coils
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
CN101448803A (zh) * 2006-03-17 2009-06-03 阿斯利康(瑞典)有限公司 用作5-ht6调节剂的四氢萘
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
CN110179988A (zh) * 2019-07-10 2019-08-30 王大伟 五羟色胺再摄取抑制剂和单胺氧化酶抑制剂联合在制备治疗抑郁症或早泄药物中的应用
IL321485A (en) * 2022-12-14 2025-08-01 Luminous Mind Inc Treatment of psychological symptoms affecting other medical conditions (PFAOMC)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
ES2162792T3 (es) * 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
KR20010024087A (ko) 2001-03-26
PL339368A1 (en) 2000-12-18
DK1014986T3 (da) 2004-10-25
US6159970A (en) 2000-12-12
CA2302204A1 (en) 1999-03-25
IS5401A (is) 2000-03-14
BR9812236A (pt) 2000-07-18
DE69825062D1 (de) 2004-08-19
PT1014986E (pt) 2004-10-29
CN1278727A (zh) 2001-01-03
ES2222603T3 (es) 2005-02-01
ATE270889T1 (de) 2004-07-15
WO1999013878A1 (en) 1999-03-25
EP1014986B1 (en) 2004-07-14
AU9193198A (en) 1999-04-05
NO20001400L (no) 2000-05-05
SE9703376D0 (sv) 1997-09-18
NO20001400D0 (no) 2000-03-17
AU752719B2 (en) 2002-09-26
JP2001516719A (ja) 2001-10-02
SK2832000A3 (en) 2000-09-12
EE200000146A (et) 2001-02-15
ID25789A (id) 2000-11-02
AR013503A1 (es) 2000-12-27
TR200000725T2 (tr) 2000-08-21
KR20010024084A (ko) 2001-03-26
DE69825062T2 (de) 2005-08-25
EP1014986A1 (en) 2000-07-05
MXPA00002616A (es) 2002-04-24
HUP0100621A2 (hu) 2001-08-28
IL134775A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
IL134775A0 (en) A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST
EP1115389A4 (en) ANTAGONISTS AND AGONISTS OF FRUCTOSAMINE OXIDASE
IL134776A0 (en) A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST
PL337781A1 (en) Antagonists and reverse antagonists of glucogene
HUP0101809A2 (hu) 5-és 3-as típusú 17béta-hidroxi-szteroid dehidrogenáz inhibitorok és ezeket tartalmazó gyógyászati készítmények
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
PL335054A1 (en) Combination of agents for inhibiting carcinogenesis comprising benzimidazole and possibly a potentiator
ZA974147B (en) Somatostatin agonists and antagonists.
AU4772497A (en) Constrained somatostatin agonists and antagonists
PL341335A1 (en) Combination of ace and mmp inhibitors
IL117988A0 (en) A new combination of an inhibitor and an antagonist
PL334975A1 (en) Application of gasto-intestinal lipase inhibitors
HUP9801227A3 (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors and their use
GR3034514T3 (en) Benzonitriles and -fluorides as 5-HT agonists and antagonists
PL337725A1 (en) Inhibitors of proteases
AU6417198A (en) Cytoprotective agents comprising monoamine oxidase inhibitors
GB2338014B (en) Novel drilling device and method of use
EP1069901A4 (en) CALCILYTIC COMPOUNDS AND THEIR USE
ZA9810272B (en) Formulation of a cobination of a opioid and a alpha-adrenergic agonist and the use thereof
EP1023269A4 (en) BETA3-ADRENORECEPTOR AGONISTS, AGONIST COMPOSITIONS AND METHODS OF USE
IL134774A0 (en) A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST
ZA9710989B (en) Polyprolyl inhibitors of cyclophilin
PL352387A1 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
HK1032738A (en) A combination of a monoamine oxidase inhibitor and a h5-ht 1 beta antagonist or partial agonist
SI1021183T1 (en) A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST